期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 110, 期 4, 页码 860-862出版社
WILEY
DOI: 10.1002/cpt.2215
关键词
-
Concerns about diminished antiplatelet effects of clopidogrel in CYP2C19 poor metabolizers led the FDA to update the product label with a black box warning, but there is no mention of CYP2C19 intermediate metabolizers in the warning. Accumulating evidence over the past decade suggests that CYP2C19 IMs are also at risk of diminished antiplatelet effects.
In 2010, concern over the diminished antiplatelet effects of clopidogrel led the US Food and Drug Administration (FDA) to update the product label to include a black box warning (BBW) on the use of clopidogrel in cytochrome P450 2C19 (CYP2C19) poor metabolizers (PMs).(1) However, there is no mention of CYP2C19 intermediate metabolizers (IMs) in the BBW; over the last decade, additional evidence has accumulated showing CYP2C19 IMs are also at risk of diminished antiplatelet effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据